EUIPO trademark

ISONOVA

RegisteredEUIPOWord markClass 9Class 42

"ISONOVA" is a word mark owned by Isomorphic Labs Limited, filed at the EUIPO on May 27, 2024. It is registered and covers classes 9 and 42.

View Isomorphic Labs Limited portfolioGet this data via the API
Official EUIPO record
ISONOVA
Word mark as filed with the EUIPO
Status
Registered
Since October 24, 2024
Filed
May 27, 2024
Registered
October 23, 2024
Expires
May 27, 2034
Application no.
019032717
Registration no.
019032717
Office
EUIPO
European Union Intellectual Property Office
Mark type
Word mark
2 classes
Ownership

Who owns ISONOVA

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Isomorphic Labs Limited

19 trademarks in the portfolioView company

Representative

Fish & Richardson P.C.

Fish & Richardson P.C

Goods and services

What the mark covers

The products and services ISONOVA is filed for, grouped by Nice class.

  • Downloadable software for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; downloadable computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for predicting protein structure, discovering drugs, designing drug candidates, biologic product development, and pharmaceutical product development; downloadable computer software for manipulating received or inputted data generated in a virtual space in connection with artificial intelligence methods, machine learning methods, natural language processing, natural language understanding, dialog systems, voice and speech recognition and text to speech systems, natural language human-machine interfaces, and predictive assistance technologies, for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer programs for manipulating received or inputted data generated in a virtual space in connection with artificial intelligence methods, machine learning methods, natural language processing, natural language understanding, dialog systems, voice and speech recognition and text to speech systems, natural language human-machine interfaces, and predictive assistance technologies, for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer software algorithms for manipulating received or inputted data generated in a virtual space in connection with artificial intelligence methods, machine learning methods, natural language processing, natural language understanding, dialog systems, voice and speech recognition and text to speech systems, natural language human-machine interfaces, and predictive assistance technologies, for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; downloadable computer software for conducting therapeutic product research and development; downloadable computer software for discovering, optimizing and developing drugs; downloadable computer software for designing and developing drug candidates

  • Software as a service (SAAS) services featuring software for protein structure prediction, drug discovery, drug candidate design, biological product development, and pharmaceutical product development; software as a service (SAAS) services featuring software using artificial intelligence, machine learning, deep learning, or reinforcement learning for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; platform as a service (PaaS) services featuring software for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; platform as a service (PaaS) services featuring software using artificial intelligence, machine learning, deep learning, and reinforcement learning for protein structure prediction, drug discovery, development of biologic materials, development of biologic products, and pharmaceutical product development; advanced product research, design and development in the field of artificial intelligence for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; research and development in the fields of artificial intelligence, machine learning, deep learning, and reinforcement learning technologies for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; technology research in the field of artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; providing online, non-downloadable computer software platforms for protein structure prediction, drug discovery, drug candidate design, biologic material development, , and pharmaceutical product development; providing online, non-downloadable computer software platforms using artificial intelligence, machine learning, deep learning, or reinforcement learning for protein structure prediction, drug discovery, drug candidate design, biological produce development, and pharmaceutical product development; testing of computing methods, computer software algorithms, computer software, and computer hardware for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; scientific, pharmaceutical, biotech, medical, and artificial intelligence research; scientific research in the field of computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for medical research, pharmaceutical research, biotech research, protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; product research and development; medical, pharmaceutical, biotech, and scientific research in the field of protein structure prediction, drug discovery, drug candidate design, biologic product development, pharmaceutical product development, and computational biology; scientific and technological services, namely, scientific research in the fields of analytics and data mining, data analysis, data transformation, data visualization, statistical analysis, artificial intelligence, machine learning, virtual reality, science, chemistry, medicinal chemistry, physics, biology, and digital biology, all for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer aided data analysis for scientific research purposes in the fields of artificial intelligence, machine learning, deep learning, reinforcement learning, building neural networks, data tree search, high performance computing, distributed computing, cloud computing, all for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer aided data analysis for scientific research purposes in the fields of analytics and data mining, virtual reality, augmented reality, chemistry, medicinal chemistry, physics, biology, and digital biology, all for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer modelling services; technical or scientific services for the analysis of compositions of matter; technical consulting in the field of pharmaceutical studies; drug discovery, drug design, optimization and development services; research and development of therapeutic products; drug discovery, optimization and development services; therapeutic and diagnostic candidate design services

History

What has happened so far

Steps recorded by the EUIPO, newest first.

  1. Bulletin 2025/182 Section C.2.2
  2. Bulletin 2024/205 Section B.1
  3. Bulletin 2024/133 Section A.1
FAQ

About ISONOVA

Who owns the trademark "ISONOVA"?

The EUIPO trademark "ISONOVA" (application 019032717) is owned by Isomorphic Labs Limited.

What is the status of "ISONOVA"?

Its status at the EUIPO is: registered.

When was "ISONOVA" registered?

It was registered on October 23, 2024 and is due to expire on May 27, 2034.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull ISONOVA and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d4749-9b48-7487-a236-e3b786b02036
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d4749-9b48-7487-a236-e3b786b02036",
  "object": "trademark",
  "mark_text": "ISONOVA",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "EM",
  "application_number": "019032717",
  "filing_date": "2024-05-27",
  "nice_classes": [
    9,
    42
  ],
  "owners": [
    {
      "name": "Isomorphic Labs Limited",
      "entity_id": "ent_019eb7c9-3699-730a-bc89-d456a3a4d4bf"
    }
  ]
}